Bioequivalence study of generic nirmatrelvir in healthy volunteers

• Autori principali: R. A. Oseshnyuk (Autore), A. G. Nikiforova (Autore), A. Yu. Boroduleva (Autore), P. D. Sobolev (Autore), S. A. Lesnichuk (Autore), B. B. Garyaev (Autore), A. A. Abramova (Autore), V. G. Mozgovaya (Autore), O. V. Filon (Autore), A. V. Zinkovskaya (Autore), A. N. Dolgorukova (Autore), E. K. Khanonina (Autore), V. G. Ignatiev (Autore), M. Yu. Samsonov (Autore)
• Natura: Libro
• Pubblicazione: Volgograd State Medical University, Pyatigorsk Medical and Pharmaceutical Institute, 2023-05-01T00:00:00Z.
• Soggetti: article
• Accesso online: Connect to this object online.

Nirmatrelvir is an antiviral drug that, in combination with ritonavir, is an effective agent for the etiotropic therapy of patients with mild to moderate COVID-19.The aim of the study was to evaluate bioequivalence of the generic drug nirmatrelvir Аrpaxel in combination with ritonavir and the origin...